The study is being conducted at Karolinska University Hospital Huddinge and at Uddevalla Hospital.
\nThe treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels of OsteoDex
\n(ODX) are studied, 3mg\/kg body weight, 6mg\/kg, and 9mg\/kg. The Principal Investigator (PI) is Dr
\nKatarina Uttervall, MD, PhD, Department of Hematology\/HERM, Karolinska University Hospital
\nHuddinge. Dr Dorota Knut is the principal investigator at the Department of Hematology at Uddevalla
\nHospital. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital
\nSolna, NKS. Adult myeloma patients with progressive treatment-resistant disease, who have
\npreviously received 1\u20135 prior lines of therapy, are included in the study. The primary objective is to
\nconfirm ODX safety and tolerability and with a secondary objective to demonstrate indications of
\ntreatment response.<\/p>\n
The last patient in dose group 2 (6mg\/kg) was finished in week 50 (7 doses) and has had his last visit.
\nThe patient then continued to have stable disease. All patients in dose group 3 (9mg\/kg) have
\nachieved stable disease and will be completed by the end of February. No significant ODX related side
\neffects have been noted. Patients with stable disease after completion of ODX treatment are followed
\nuntil new progress to map how long the disease-inhibiting effect persists. Data obtained so far show
\nthat the disease-inhibiting effect in some cases persists for months and at most up to six months
\nwithout initiation of other cancer treatment.<\/p>\n
The results show that all patients responded positively to the ODX treatment, with a transition from
\nprogressive disease to stable disease.<\/p>\n
“We are very pleased with the study results obtained so far, which are far better than we dared to
\nhope for. These strengthen the image of ODX as a candidate for the treatment of treatment-resistant
\nmultiple myeloma, and also without significant side effects,” says CEO Anders R Holmberg.<\/p>\n